Cardiovasc Prev Pharmacother.  2021 Jan;3(1):10-14. 10.36011/cpp.2021.3.e3.

Vasopressin Receptor Antagonist, Tolvaptan, for Treating Hyponatremia in Patients with Heart Failure

• Kim KJ

• KMID: 2536947
• DOI: http://doi.org/10.36011/cpp.2021.3.e3

Abstract

Hyponatremia is common in hospital setting in patients with heart failure and is associated with increased morbidity and mortality. However, despite these complications, appropriate treatment strategies other than established therapies such as hypertonic saline, loop diuretics, and fluid restriction are limited. Tolvaptan, a vasopressin receptor antagonist, has aquaretic effects that excrete free water and dilutes urine, thereby increasing serum sodium concentration. This new approach might be a landmark in the treatment of hyponatremia as there is a lack of controlled studies in this field. However, regardless of the associated advantage, tolvaptan is recommended to be used for less than 30 days owing to the possibility of liver injury. This study is aimed to present the clinical use of tolvaptan for hyponatremia in patients with heart failure.

Keyword

Antidiuretic hormone receptor antagonists; Heart failure; Hyponatremia; Tolvaptan; Vasopressins

Reference

1. Oliver G, Schäfer EA. On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication. J Physiol. 1895; 18:277–279.

2. Von den Velden R. Die nierenwirkung von hypophysenextrakten beim menschen. Berlin Klin Wochenshr. 1913; 50:2083–6.

3. Berl T. Vasopressin antagonists. N Engl J Med. 2015; 372:2207–2216.

4. Turner RA, Pierce JG, du Vigneaud V. The purification and the amino acid content of vasopressin preparations. J Biol Chem. 1951; 191:21–28.

5. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992; 357:333–335.

6. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem. 1994; 269:3304–3310.

7. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007; 67:847–858.

8. Donzé JD, Beeler PE, Bates DW. Impact of hyponatremia correction on the risk for 30-day readmission and death in patients with congestive heart failure. Am J Med. 2016; 129:836–842.

9. Rodriguez M, Hernandez M, Cheungpasitporn W, Kashani KB, Riaz I, Rangaswami J, Herzog E, Guglin M, Krittanawong C. Hyponatremia in heart failure: pathogenesis and management. Curr Cardiol Rev. 2019; 15:252–261.

10. Rosner MH. Hyponatremia in heart failure: the role of arginine vasopressin and diuretics. Cardiovasc Drugs Ther. 2009; 23:307–315.

11. Filippatos TD, Elisaf MS. Hyponatremia in patients with heart failure. World J Cardiol. 2013; 5:317–328.

12. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355:2099–2112.

13. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007; 297:1319–1331.

14. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010; 21:705–712.

15. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21:137–155.

16. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006; 290:F273–F278.

17. Epperla N, Landeck J, Sabbagh S. Osmotic demyelination syndrome. WMJ. 2014; 113:197–198.

18. Malhotra I, Gopinath S, Janga KC, Greenberg S, Sharma SK, Tarkovsky R. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans. Case Rep Endocrinol. 2014; 2014:807054.

19. Lehrich RW, Ortiz-Melo DI, Patel MB, Greenberg A. Role of vaptans in the management of hyponatremia. Am J Kidney Dis. 2013; 62:364–376.

20. Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015; 38:1103–1113.

21. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS; Sergeyeva O; REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017; 377:1930–1942.